Evidence map›Paper›PMID 37197696›Full record

ArticleInfection and drug resistance2023

Thirty-Day Outcomes of Young and Middle-Aged Adults Admitted with Severe COVID-19 in Uganda: A Retrospective Cohort Study.

Tonny Kyagambiddwa, Timothy Mwanje Kintu, Emmanuel Miiro, Franchesca Nabalamba, Gloria Suubi Asiimwe, Anne Marion Namutebi, Fardous C Abeya, Boniface A Lumori, Isaac Ijuka, Rose K Muhindo and 5 more

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Tonny Kyagambiddwa *Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0003-4411-2672
Timothy Mwanje Kintu *Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0002-5513-5899
Emmanuel Miiro *Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0001-5039-9900
Franchesca NabalambaFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Gloria Suubi AsiimweFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Anne Marion NamutebiKabale Regional Referral Hospital, Kabale, Uganda.
Fardous C AbeyaDepartment of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Boniface A LumoriDepartment of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Isaac IjukaMayanja Memorial Hospital, Mbarara, Uganda.
Rose K MuhindoFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Andrew MutekangaFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0003-3780-2202
Richard MusinguziMasaka Regional Referral Hospital, Masaka, Uganda.ORCID 0000-0002-0323-1862
Francis NatuhweraFort Portal Regional Referral Hospital, Fort Portal, Uganda.
Joseph NgonziFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Edwin NuwagiraDepartment of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0001-7526-9504
Mbarara University of Science and Technology · UGFort Portal Hospital · UGKabale Hospital · UGMasaka Hospital · UG

Funding

Multi-morbidity in Uganda Research Capacity Initiative (MURCI) at Mbarara University of Science and TechnologyD43TW011632 · FIC · MBARARA UNIVERSITY/SCIENCE/ TECHNOLOGY · PI BAJUNIRWE, FRANCIS · 2020 to 2024
$1.2M
FIC NIH HHS D43 TW011632
6 · The paper itself

Abstract

Background: There is scarcity of data regarding young and middle-aged adults hospitalized with severe Corona Virus Disease 2019 (COVID-19) in Africa. In this study, we describe the clinical characteristics and 30-day survival among adults aged 18 to 49 years admitted with severe COVID-19 in Uganda. Methods: We reviewed treatment records of patients admitted with severe COVID-19 across five COVID-19 treatment units (CTU) in Uganda. We included individuals aged 18 to 49 years, who had a positive test or met the clinical criteria for COVID-19. We defined severe COVID-19 as having an oxygen saturation <94%, lung infiltrates >50% on imaging and presence of a co-morbidity that required admission in the CTU. Our main outcome was the 30-day survival from the time of admission. We used a Cox proportional hazards model to determine the factors associated with 30-day survival at a 5% level of significance. Results: Of the 246 patient files reviewed, 50.8% (n = 125) were male, the mean ± (standard deviation) age was 39 ± 8 years, majority presented with cough, 85.8% (n = 211) and median C-reactive protein (interquartile range) was 48 (47.5, 178.8) mg/L. The 30-day mortality was 23.9% (59/246). At admission, anemia (hazard ratio (HR): 3.00, 95% confidence interval (CI), 1.32-6.82; p = 0.009) and altered mental state (GCS <15) (HR: 6.89, 95% CI: 1.48-32.08, p = 0.014) were significant predictors of 30-day mortality. Conclusion: There was a high 30-day mortality among young and middle-aged adults with severe COVID-19 in Uganda. Early recognition and targeted management of anemia and altered consciousness are needed to improve clinical outcomes.

Indexed as

COVID-19mortalityUgandayoung and middle-aged adults

Identifiers

PMID37197696
PMCPMC10184892
OpenAlexW4377012089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.